modelLisinopril
Extends from Pharmacolibrary.Drugs.ATC.C.C09AA03.
Information
| name: | Lisinopril | |
| ATC code: | C09AA03 | route: | oral |
| compartments: | 1 | |
| dosage: | 20 | mg |
| volume of distribution: | 58 | L |
| clearance: | 220 | ml/min |
| other parameters in model implementation | ||
Lisinopril is an angiotensin-converting enzyme (ACE) inhibitor used primarily for the treatment of hypertension, heart failure, and post-myocardial infarction. It is an oral medication approved and widely used in clinical practice today.
Pharmacokinetics
Pharmacokinetic parameters are reported for healthy adult volunteers after single oral administration.
References
Sandra, L, et al., & Vermeulen, A (2024). Population pharmacokinetics of lisinopril in hypertensive children and adolescents with normal to mildly reduced kidney function. British journal of clinical pharmacology 90(2) 504–515. DOI:10.1111/bcp.15936 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37864281
Winnicki, W, et al., & Sengoelge, G (2012). Lisinopril pharmacokinetics and erythropoietin requirement in haemodialysis patients. European journal of clinical investigation 42(10) 1087–1093. DOI:10.1111/j.1365-2362.2012.02699.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/22845880
Trachtman, H, et al., & Patel, UD (2015). Pharmacokinetics, Pharmacodynamics, and Safety of Lisinopril in Pediatric Kidney Transplant Patients: Implications for Starting Dose Selection. Clinical pharmacology and therapeutics 98(1) 25–33. DOI:10.1002/cpt.127 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25807932
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)